Firing FDA Chief: Trump Plans Makary Ouster
WSJ reports Trump plans to fire FDA Commissioner Makary after 14 months marked by mass departures, a vaping feud, and warnings of political capture.
WSJ reports Trump plans to fire FDA Commissioner Makary after 14 months marked by mass departures, a vaping feud, and warnings of political capture.
WSJ reports Trump plans to oust FDA Commissioner Makary after 14 months of unprecedented turnover and a White House battle over flavored vapes.
France has escalated its X content probe to a criminal case against Musk and Yaccarino, who could face indictment if they don't appear.
The CBLR's revised eligibility rules and recalibrated leverage ratio mean every community bank must decide by July 1 if it still qualifies.
Trump's 100% drug tariff has a two-tier problem: big pharma cut deals, small- and mid-sized drugmakers are still in the line of fire.
FDA classified Biogen and Eisai's Leqembi SubQ initiation filing as a major amendment, moving the verdict from May 24 to August 24.
Odyssey Therapeutics priced a $304M IPO at $18 per share, at the top of its range, with $135M earmarked for a RIPK2 inhibitor in ulcerative colitis.
Lilly's $4.5B Indiana bet includes the company's first genetic medicine plant and what could become the largest API site in U.S. history.
When U.S. companies thought they were hiring domestic IT workers, the paychecks landed in Pyongyang. Two Americans just learned the price.
Anthropic's Mythos triggered an April 7 emergency meeting with big-bank CEOs. The Fed, OCC, and FDIC now say model risk rules don't cover gen AI.
Character.AI faces a Pennsylvania lawsuit for passing a chatbot off as a licensed physician. State AGs don't need federal AI law to move.
Roche is dropping $750M upfront for PathAI, with another $300M in milestones riding on a pathology software platform it wants to take global.
Angelini Pharma dropped $4.1B on Catalyst and its trio of FDA-approved rare neurology treatments; the per-share premium wasn't disclosed.
GSK paid up to $1B for SiranBio's Phase 1 siRNA asset targeting ALK7, doubling down on cardiometabolic bets while GLP-1 rivals pile up.
Four Chime customers allege Iran-linked Team 313 stole Social Security numbers and account credentials; Chime says no member data was compromised.